Close

We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Find out more
For more information, go to www.arthritisresearchuk.org

Glucosamine Corner

Issue 31 Synovium (Autumn 2010)

Download this issue (opens in new window)(152 KB)

We are always impressed with and somewhat curious about the attention research involving glucosamine and similar nutritional supplements receives. Both the studies cited here reached the national media.

A double-blind, randomised controlled trial in 250 patients attending a chronic back pain clinic in Oslo1 demonstrated that 1500 mg of glucosamine sulphate was not significantly different from placebo in treating back pain. The subjects were required to be over 25, have experienced low back pain and have had a recent MRI scan demonstrating degenerative change in the lumbar spine. Should we be disappointed by this? We don’t think so. Given that we know that in 85% of patients with back pain a structural pain generator cannot be confidently identified – and it is assumed that the cause is musculoligamentous2 – and that degenerative change on imaging correlates poorly with experience of symptoms, we wonder why glucosamine might be considered potentially useful treatment for back pain in the first place.

Secondly, a meta-analysis of studies comparing glucosamine, chondroitin and placebo in treating the pain of osteoarthritis of the hip and knee3 concluded that the supplements had no effect. The study included 10 trials of glucosamine sulphate, glucosamine hydrochloride and chondroitin sulphate. Synovium has previously reported that the evidence supporting glucosamine sulphate is modest and that there is no evidence to support the effectiveness of glucosamine hydrochloride. So would we expect that combining results from studies of both supplements would reveal significant benefits? Clearly there remains insufficient evidence to justify prescribing what are, after all, nutritional supplements – not drugs – for all our patients with osteoarthritis.

Synovium archives

Browse previous issues of Synovium (all issues available as downloadable PDFs)
For more information, go to www.arthritisresearchuk.org.
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.